Draft Niosh Hazardous Drugs List 2020

This information is distributed solely for the purpose of pre-dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention or the National Institute for Occupational Safety and Health. It does not represent and should not

be construed to represent any agency determination or policy.

NIOSH List of Hazardous Drugs in Healthcare Settings, 2020

DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health

This information is distributed solely for the purpose of pre-dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention or the National Institute for Occupational Safety and Health. It does not

represent and should not be construed to represent any agency determination or policy.

INSIDE FRONT COVER PAGE LEFT INTENTIONALLY BLANK

1

This information is distributed solely for the purpose of pre-dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention or the National Institute for Occupational Safety and Health. It does not

represent and should not be construed to represent any agency determination or policy.

NIOSH List of Hazardous Drugs in Healthcare Settings, 2020

DEPARTMENT OF HEATH AND HUMAN SERVICES Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health

2

This information is distributed solely for the purpose of pre-dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention or the National Institute for Occupational Safety and Health. It does not

represent and should not be construed to represent any agency determination or policy.

This document is in the public domain and may be freely copied or reprinted

Disclaimer

Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations of websites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these websites.

Ordering Information

To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1-800-CDC-INFO (1-800-232-4636) TTY: 1-888-232-6348 CDC-INFO: or visit the NIOSH website at niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting niosh/eNews

Suggested Citation

NIOSH [2020]. NIOSH list of hazardous drugs in healthcare settings 2020. By Connor TH, MacKenzie BA, DeBord DG, Trout DB, O'Callaghan JP, Ovesen JL, Whittaker C. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication Number 2020-xxx (Supersedes 2016-161) 2020-xxx

3

This information is distributed solely for the purpose of pre-dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention or the National Institute for Occupational Safety and Health. It does not

represent and should not be construed to represent any agency determination or policy.

Acknowledgements

The following NIOSH individuals screened and reviewed the information on hazardous drugs to develop the List and prepare this document:

Marissa Alexander-Scott Jim O'Callaghan Doug Trout Carissa Rocheleau Ainsley Weston Chris Whittaker

For significant contributions to the development and review of this document, the authors acknowledge the following NIOSH contributors:

Ann Berry Paul Middendorf John Piacentino Paul Schulte

External Reviewers

The following individuals made substantial contributions to the preparation of this List:

Shekhar Mehta, PharmD, MS American Society of Health-System Pharmacists

Melissa McDiarmid, MD, MPH, DABT University of Maryland

Bruce Naumann, PhD, DABT Merck

Michael Olson, PhD, ATS SafeBridge Consultants, Inc

Marty Polovich, PhD, RN, AOCN Georgia State University

Trish Weideman, PhD Genentech, Inc.

Vaiyapuri Subramaniam, PharmD, MS, FCP, FASHP, FASCP Department of Veterans AffairsMarian Condon, MS, RN University of Maryland

Wendelyn Schmidt, PhD Food and Drug Administration

Chris Fausel, PharmD, MHA, BCOP Indiana University Health

Michael Hodgson, MD, MPH Occupational Safety and Health Administration

Janet Gould, PhD, DABT Bristol-Myers Squibb Company

4

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download